3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Breast
1
Conditions
Colorectal Neoplasms
24
Pancreatic Neoplasms
21
Neoplasm Metastasis
16
Neuroblastoma
8
Rhabdomyosarcoma
6
Lung Neoplasms
6
Colonic Neoplasms
6
Rectal Neoplasms
5
Neoplasms
5
Esophageal Squamous Cell Carcinoma
5
Stomach Neoplasms
4
Small Cell Lung Carcinoma
4
Sarcoma, Ewing
4
Sarcoma
4
Esophageal Neoplasms
4
Adenocarcinoma Of Esophagus
4
Endometrial Neoplasms
3
Cholangiocarcinoma
3
Carcinoma, Non-Small-Cell Lung
3
Biliary Tract Neoplasms
3
Wilms Tumor
2
Pathologic Complete Response
2
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Ovarian Neoplasms
2
Kidney Neoplasms
2
Hereditary Sensory and Autonomic Neuropathies
2
Glioma
2
Carcinoma, Neuroendocrine
2
Carcinoma, Hepatocellular
2
Breast Neoplasms
2
Interventions
pembrolizumab
47
Carboplatin
35
Paclitaxel
28
Specimen Handling
20
Cyclophosphamide
17
Capecitabine
16
Magnetic Resonance Spectroscopy
15
sacituzumab govitecan
13
Gemcitabine
13
Biopsy
13
Taxes
12
130-nm albumin-bound paclitaxel
11
Albumin-Bound Paclitaxel
9
olaparib
8
Doxorubicin
8
Nivolumab
7
fludarabine
6
Cisplatin
6
eribulin
5
atezolizumab
5
Radiotherapy
5
Docetaxel
5
durvalumab
4
Immunoglobulin G
4
Fulvestrant
4
Epirubicin
4
Drug Therapy
4
Bevacizumab
4
veliparib
3
toripalimab
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Triple Negative Breast Neoplasms
×
Irinotecan
×
90 days
×
Clear all
NCT01042379
2026-05-06
I-SPY
QuantumLeap Healthcare Collaborative
Phase 2
Recruiting
5,000 enrolled